$4M Private Placement Provides Lifeline for Financially Distressed Arcadia Biosciences
RKDA sits 46% above its 52-week low of $0.8 on elevated volume (41× avg).
Summary
Arcadia Biosciences announced a $4 million private placement of common stock and warrants, priced at $1.03 per share. This capital raise is crucial for the company, which reported a $4.4 million net loss in Q1 2026 and reiterated a going concern warning in its May 14th 10-Q. The company also disclosed a $4.0 million debt default and faces a Nasdaq delisting threat. While providing much-needed working capital, the offering is highly dilutive, representing nearly double the company's current market capitalization.
At the time of this announcement, RKDA was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.80 to $6.71. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.